These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

433 related items for PubMed ID: 15384859

  • 1. [Elevated expression of matrix metalloproteinase-9, and fibronectin concentration in recurrent epithelial ovarian cancer].
    Demeter A, Szirmai K, Oláh J, Papp Z, Jeney A.
    Orv Hetil; 2004 Aug 01; 145(31):1617-24. PubMed ID: 15384859
    [Abstract] [Full Text] [Related]

  • 2. [Assessment of prognostic factors in common ovarian tumors of varying malignancy].
    Demeter A, Várkonyi T, Csapó Z, Szánthó A, Oláh J, Papp Z.
    Magy Onkol; 2004 Aug 01; 48(3):259-65. PubMed ID: 15520877
    [Abstract] [Full Text] [Related]

  • 3. Molecular prognostic markers in recurrent and in non-recurrent epithelial ovarian cancer.
    Demeter A, Sziller I, Csapo Z, Olah J, Keszler G, Jeney A, Papp Z, Staub M.
    Anticancer Res; 2005 Aug 01; 25(4):2885-9. PubMed ID: 16080542
    [Abstract] [Full Text] [Related]

  • 4. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.
    Lengyel E, Schmalfeldt B, Konik E, Späthe K, Härting K, Fenn A, Berger U, Fridman R, Schmitt M, Prechtel D, Kuhn W.
    Gynecol Oncol; 2001 Aug 01; 82(2):291-8. PubMed ID: 11531282
    [Abstract] [Full Text] [Related]

  • 5. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
    Hu XX, Li L, Li DR, Zhang W, Cheng XQ, Zhang JQ, Tang BJ.
    Ai Zheng; 2004 Oct 01; 23(10):1194-8. PubMed ID: 15473934
    [Abstract] [Full Text] [Related]

  • 6. Expression of matrix metalloproteinases and related tissue inhibitors in the cyst fluids of ovarian mucinous neoplasms.
    Furuya M, Ishikura H, Kawarada Y, Ogawa Y, Sakuragi N, Fujimoto S, Yoshiki T.
    Gynecol Oncol; 2000 Aug 01; 78(2):106-12. PubMed ID: 10926788
    [Abstract] [Full Text] [Related]

  • 7. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
    Yabushita H, Shimazu M, Noguchi M, Kishida T, Narumiya H, Sawaguchi K, Noguchi M.
    Oncol Rep; 2003 Aug 01; 10(1):89-95. PubMed ID: 12469150
    [Abstract] [Full Text] [Related]

  • 8. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
    Schmalfeldt B, Prechtel D, Härting K, Späthe K, Rutke S, Konik E, Fridman R, Berger U, Schmitt M, Kuhn W, Lengyel E.
    Clin Cancer Res; 2001 Aug 01; 7(8):2396-404. PubMed ID: 11489818
    [Abstract] [Full Text] [Related]

  • 9. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors.
    Huang LW, Garrett AP, Bell DA, Welch WR, Berkowitz RS, Mok SC.
    Gynecol Oncol; 2000 Jun 01; 77(3):369-76. PubMed ID: 10831344
    [Abstract] [Full Text] [Related]

  • 10. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours.
    Määtta M, Talvensaari-Mattila A, Turpeenniemi-Hujanen T, Santala M.
    Anticancer Res; 2007 Jun 01; 27(4C):2753-8. PubMed ID: 17695443
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Expression of KiSS-1, matrix metalloproteinase-9, nuclear factor-kappaBp65 in ovarian tumour].
    Gao GL, Liu LD, Zou XS, Chen WX.
    Zhonghua Fu Chan Ke Za Zhi; 2007 Jan 01; 42(1):34-8. PubMed ID: 17331419
    [Abstract] [Full Text] [Related]

  • 15. Shed membrane fragment-associated markers for endometrial and ovarian cancers.
    Taylor DD, Lyons KS, Gerçel-Taylor C.
    Gynecol Oncol; 2002 Mar 01; 84(3):443-8. PubMed ID: 11855885
    [Abstract] [Full Text] [Related]

  • 16. Concentration of metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in the serum of patients with benign and malignant thyroid tumours treated surgically.
    Pasieka Z, Stepien H, Czyz W, Pomorski L, Kuzdak K.
    Endocr Regul; 2004 Jun 01; 38(2):57-63. PubMed ID: 15497929
    [Abstract] [Full Text] [Related]

  • 17. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression.
    Torng PL, Mao TL, Chan WY, Huang SC, Lin CT.
    Gynecol Oncol; 2004 Feb 01; 92(2):559-67. PubMed ID: 14766248
    [Abstract] [Full Text] [Related]

  • 18. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor.
    Rauvala M, Puistola U, Turpeenniemi-Hujanen T.
    Gynecol Oncol; 2005 Dec 01; 99(3):656-63. PubMed ID: 16112717
    [Abstract] [Full Text] [Related]

  • 19. Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer.
    Zhang L, Shi J, Feng J, Klocker H, Lee C, Zhang J.
    Prostate Cancer Prostatic Dis; 2004 Dec 01; 7(4):327-32. PubMed ID: 15356679
    [Abstract] [Full Text] [Related]

  • 20. [Clinical significance of matrix metalloproteinase-2 expression in patients with epithelial ovarian tumor].
    Wu X, Li H, Song J.
    Zhonghua Fu Chan Ke Za Zhi; 2001 Oct 01; 36(10):621-4. PubMed ID: 16134528
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.